Employees Retirement System of Texas Raises Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Employees Retirement System of Texas raised its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,489 shares of the company’s stock after purchasing an additional 973 shares during the quarter. Employees Retirement System of Texas’ holdings in Moderna were worth $4,333,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Corient Private Wealth LLC grew its position in shares of Moderna by 13.7% in the 4th quarter. Corient Private Wealth LLC now owns 23,682 shares of the company’s stock worth $2,355,000 after buying an additional 2,855 shares during the period. Advisory Services Network LLC grew its position in shares of Moderna by 80.4% in the 4th quarter. Advisory Services Network LLC now owns 12,715 shares of the company’s stock worth $1,265,000 after buying an additional 5,667 shares during the period. Steward Partners Investment Advisory LLC grew its position in shares of Moderna by 24.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 6,495 shares of the company’s stock worth $646,000 after buying an additional 1,258 shares during the period. Focus Financial Network Inc. ADV purchased a new stake in shares of Moderna in the 4th quarter worth about $596,000. Finally, Boston Family Office LLC purchased a new stake in Moderna during the 4th quarter valued at about $201,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 689 shares of the stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now owns 7,269 shares in the company, valued at approximately $859,486.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.36. Following the sale, the chief financial officer now owns 7,269 shares in the company, valued at approximately $859,486.56. The disclosure for this sale can be found here. Insiders have sold 78,158 shares of company stock worth $9,259,012 in the last quarter. Company insiders own 15.70% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Evercore ISI reissued an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research report on Thursday, June 27th. Jefferies Financial Group downgraded shares of Moderna from a “buy” rating to a “hold” rating and cut their price objective for the company from $120.00 to $65.00 in a research report on Friday, September 13th. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Royal Bank of Canada reissued a “sector perform” rating and set a $75.00 price objective on shares of Moderna in a research report on Thursday, September 19th. Finally, Bank of America cut their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $100.44.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $63.93 on Friday. The firm’s 50 day moving average price is $85.34 and its 200-day moving average price is $109.78. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $24.57 billion, a PE ratio of -4.08 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the prior year, the business earned ($3.62) EPS. The business’s quarterly revenue was down 29.9% on a year-over-year basis. Equities research analysts expect that Moderna, Inc. will post -9.86 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.